Novo Nordisk AS Newswire (Page 2)

Novo Nordisk AS Newswire (Page 2)

Comprehensive Real-Time News Feed for Novo Nordisk AS. (Page 2)

Results 21 - 40 of 497 in Novo Nordisk AS

  1. Novo Nordisk A/S (NVO) Upgraded to Hold by Zacks Investment ResearchRead the original story w/Photo

    Monday Jul 11 | AmericanBankingNews.com

    According to Zacks, "Novo Nordisk has a strong presence in the Diabetes Care market. Additionally, products like Victoza and Tresiba along with contributions from Saxenda and Xultophy are expected to continue boosting the top line.

    Comment?

  2. Arena: Belviq Sales Close Out Weakest Quarter In 2 YearsRead the original story w/Photo

    Monday Jul 11 | Seeking Alpha

    Many investors in Arena Pharmaceuticals have now come to the realization that Belviq will not deliver the level of revenue needed to drive the company or fund the company. That being said, it is the main source of revenue for the company, and tracking the sales remains important.

    Comment?

  3. FY2016 EPS Estimates for Novo Nordisk A/S Lifted by AnalystRead the original story w/Photo

    Monday Jul 11 | AmericanBankingNews.com

    Stock analysts at Jefferies Group increased their FY2016 earnings per share estimates for shares of Novo Nordisk A/S in a report released on Wednesday. Jefferies Group analyst J. Holford now anticipates that the brokerage will earn $2.37 per share for the year, up from their previous forecast of $2.29.

    Comment?

  4. Novo Nordisk - Saxenda Closes Out Q2 On Strong NoteRead the original story w/Photo

    Sunday Jul 10 | Seeking Alpha

    I have long stated that I invested into Novo Nordisk despite its entry into the anti-obesity sector, not because of it. I had long been familiar with the company and long been of the opinion that it was a solid company and a decent investment.

    Comment?

  5. Trenton groups are teaming up to combat obesity | EditorialRead the original story w/Photo

    Sunday Jul 10 | The Times of Trenton

    It takes a village to teach youngsters the importance of making wise choices when it comes to eating habits: baked versus fried, low-fat versus calorie-laden, apples versus puffy Cheez Doodles. And it takes that same village to hammer home the benefits of remaining active rather than languishing on a sofa with a can of high-fructose soft drink in one hand and a cheeseburger in the other.

    Comment?

  6. Novo Nordisk A/S (NVO) Shares Gap Up to $53.82Read the original story w/Photo

    Saturday Jul 9 | Daily Political

    Novo Nordisk A/S gapped up before the market opened on Thursday . The stock had previously closed at $53.65, but opened at $53.82.

    Comment?

  7. Novo Nordisk A/S (NYSE:NVO) Receives $60.00 Average PT from BrokeragesRead the original story w/Photo

    Friday Jul 8 | Daily Political

    Novo Nordisk A/S has been given an average recommendation of "Buy" by the eight research firms that are currently covering the company. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company.

    Comment?

  8. New Report Shares Details About the Global Human Growth Hormone...Read the original story w/Photo

    Thursday Jul 7 | SBWire

    Consistent with our stated policy of making available the best research material from across the globe to our ever-growing list of erudite clients, here is another report that is sure to meet their high expectations. This 2016 market research report on Global Human Growth Hormone Market Professional Survey is a meticulously undertaken study.

    Comment?

  9. Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulinRead the original story w/Photo

    Wednesday Jul 6 | Medical News

    When Amy Sweat was 19 years old, while she was in the hospital recovering from surgery, she was diagnosed with Type 2 diabetes . Ms. Sweat was treated for her diabetes, first on oral drugs, then on increasingly larger doses of insulin, but the years went by and she never was able to achieve good blood sugar control.

    Comment?

  10. Liraglutide Reduces Blood Sugars in Patients Taking Large Amounts of InsulinRead the original story

    Wednesday Jul 6 | Newswise

    July 6, 2016 - When Amy Sweat was 19 years old, while she was in the hospital recovering from surgery, she was diagnosed with Type 2 diabetes. Ms. Sweat was treated for her diabetes, first on oral drugs, then on increasingly larger doses of insulin, but the years went by and she never was able to achieve good blood sugar control.

    Comment?

  11. Novo Nordisk A/S (NVO) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Monday Jul 4 | AmericanBankingNews.com

    According to Zacks, "Novo Nordisk, which has a strong presence in the Diabetes Care market, faces tough competition from players like Eli Lilly, Sanofi and Merck. We remain concerned about the company's insulin product prices that are either subsidized or are subject to price control.

    Comment?

  12. Novo Nordisk A/S (NVO) Rating Lowered to Sell at Zacks Investment ResearchRead the original story w/Photo

    Monday Jul 4 | AmericanBankingNews.com

    According to Zacks, "Novo Nordisk, which has a strong presence in the Diabetes Care market, faces tough competition from players like Eli Lilly, Sanofi and Merck. We remain concerned about the company's insulin product prices that are either subsidized or are subject to price control.

    Comment?

  13. Novo Nordisk invests $60 mln to expand insulin plant in KalundborgRead the original story

    Monday Jul 4 | Reuters

    * Groundbreaking for the plant extension will take place Monday and the extension is expected to is expected to be completed at the end of 2018, the company said.

    Comment?

  14. Goldman Sachs Group Inc. Lowers Novo Nordisk A/S (NVO) to BuyRead the original story w/Photo

    Sunday Jul 3 | AmericanBankingNews.com

    Other analysts also recently issued reports about the company. Citigroup Inc. reiterated a "buy" rating on shares of Novo Nordisk A/S in a report on Friday, April 1st.

    Comment?

  15. Nintai Charitable Trust's -nd-Quarter ResultsRead the original story w/Photo

    Friday Jul 1 | GuruFocus.com

    The second quarter saw some dramatic movement at the end of June as Britain voted to exit the European Union. The reaction to this left the markets down during the quarter.

    Comment?

  16. Novo Nordisk A/S (NVO) Downgraded by Goldman SachsRead the original story w/Photo

    Friday Jul 1 | Daily Political

    A number of institutional investors have recently modified their holdings of NVO. Cullinan Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the first quarter valued at $244,000.

    Comment?

  17. Oramed: The Atypical Biotechnology Company With Great Upside PotentialRead the original story w/Photo

    Friday Jul 1 | Seeking Alpha

    Oramed , the biotech company involved in the research and development of orally deliverable insulin, is a great investment opportunity for investors that are looking for a growing small stock in the biotechnology industry. Oramed is currently facing an interesting challenge in the diabetes market.

    Comment?

  18. Novo Nordisk to fund child health initiative in TrentonRead the original story w/Photo

    Friday Jul 1 | The Jersey Journal

    TRENTON - Pharmaceutical giant Novo Nordisk will fund an initiative to improve the health of Trenton's children and families, officials said. The program, called the Community Health Collaborative, will be coordinated by the Trenton Health Team and will look to educate parents and promote physical activity and healthy food choices for grade school children.

    Comment?

  19. Status regarding Novo Nordisk's holding of its own sharesRead the original story

    Thursday Jun 30 | P&T Community

    In continuation of the company's announcements dated 3 February 2016 and 29 April 2016 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S and its wholly-owned affiliates on 30 June 2016 owned 18,377,645 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 3,675,529 or 0.7% of the total share capital. In the second quarter of 2016 a total of 9,932,000 B shares were repurchased, and 227,000 B shares were disposed to employees in connection with employee incentive programmes.

    Comment?

  20. Hemophilia A Drug Consumption Industry Demand, Supply and Forecast 2021Read the original story

    Thursday Jun 30 | Emailwire.com

    ReportsWeb.com has announced the addition of the 'Global Hemophilia A Drug Consumption 2016 Market Research Report', the report focuses on global major leading industry players with information such as company profiles, product picture and specification. The Global Hemophilia A Drug Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Hemophilia A Drug market.

    Comment?